WO2002040640A3 - Methods of using cd8+/tcr- facilitating cells (fc) for the engraftment of purified hematopoietic stem cells (hsc) - Google Patents

Methods of using cd8+/tcr- facilitating cells (fc) for the engraftment of purified hematopoietic stem cells (hsc) Download PDF

Info

Publication number
WO2002040640A3
WO2002040640A3 PCT/US2001/045312 US0145312W WO0240640A3 WO 2002040640 A3 WO2002040640 A3 WO 2002040640A3 US 0145312 W US0145312 W US 0145312W WO 0240640 A3 WO0240640 A3 WO 0240640A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
hsc
tcr
hematopoietic stem
engraftment
Prior art date
Application number
PCT/US2001/045312
Other languages
French (fr)
Other versions
WO2002040640A2 (en
Inventor
Suzanne T Ildstad
Original Assignee
Univ Louisville Res Found
Suzanne T Ildstad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Louisville Res Found, Suzanne T Ildstad filed Critical Univ Louisville Res Found
Priority to AU2002220031A priority Critical patent/AU2002220031A1/en
Publication of WO2002040640A2 publication Critical patent/WO2002040640A2/en
Publication of WO2002040640A3 publication Critical patent/WO2002040640A3/en
Priority to US11/004,046 priority patent/US20060018885A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to the identification and use of facilitating cells that are critical for engagement of purified 'hematopoietic stem cells' (HSC), and more specifically this invention relates to two cell populations of CD8+ cells, that is, CD8+/TCR- 'facilitating cells' (FC) which are critical to 'hematopoietic stem cells' (HSC) survival and self-renewal, and CD8+/TCR+ cells which enhance the level of donor engraftment but do not promote long-term, durable engraftment. These two cell populations may have a wide range of applications, including but not limited to, hematopoietic reconstitution by bone marrow transplantation for the treatment of cancers, anemias, autoimmunity, immunodeficiency, viral infections and metabolic disorders as well as facilitation of solid organ, tissue and cellular transplantation.
PCT/US2001/045312 2000-11-14 2001-11-14 Methods of using cd8+/tcr- facilitating cells (fc) for the engraftment of purified hematopoietic stem cells (hsc) WO2002040640A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002220031A AU2002220031A1 (en) 2000-11-14 2001-11-14 Methods of using cd8+/tcr- facilitating cells (fc) for the engraftment of purified hematopoietic stem cells (hsc)
US11/004,046 US20060018885A1 (en) 2000-11-14 2004-12-03 Methods for increasing HSC graft efficiency

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24889500P 2000-11-14 2000-11-14
US60/248,895 2000-11-14

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/438,264 Continuation US20040228845A1 (en) 2000-11-14 2003-05-14 Methods of using CD8+/TCR- facilitating cells (FC) for the engraftment of purified hematopoietic stem cells (HSC)

Publications (2)

Publication Number Publication Date
WO2002040640A2 WO2002040640A2 (en) 2002-05-23
WO2002040640A3 true WO2002040640A3 (en) 2002-09-12

Family

ID=22941146

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/045312 WO2002040640A2 (en) 2000-11-14 2001-11-14 Methods of using cd8+/tcr- facilitating cells (fc) for the engraftment of purified hematopoietic stem cells (hsc)

Country Status (2)

Country Link
AU (1) AU2002220031A1 (en)
WO (1) WO2002040640A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10131971A1 (en) * 2001-07-02 2003-01-30 Cytonet Gmbh & Co Kg Preparation of hematopoietic stem cell preparations, useful in transplants for treating leukemia and viral infections, does not induce graft versus host disease
AU2002322857A1 (en) * 2001-08-01 2003-02-17 Jewish Hospital Healthcare Services, Inc. Cellular compositions which facilitate engraftment of hematopoietic stem cells while minimizing the risk of gvhd
US8632768B2 (en) * 2008-05-30 2014-01-21 University Of Louisville Research Foundation, Inc. Human facilitating cells
US11291686B2 (en) 2008-05-30 2022-04-05 University Of Louisville Research Foundation, Inc. Human facilitating cells
EP2797421B1 (en) 2011-12-22 2020-05-20 Yeda Research And Development Co. Ltd. A combination therapy for a stable and long term engraftment using specific protocols for t/b cell depletion
WO2013173076A1 (en) * 2012-05-04 2013-11-21 University Of Southern California Methods and compositions for generating and using allogeneic suppressor cells
EP2961431A4 (en) 2013-02-26 2016-01-20 Univ Leland Stanford Junior Combined organ and hematopoietic cells for transplantation tolerance of grafts
US11273179B2 (en) 2018-03-12 2022-03-15 Medeor Therapeutics, Inc. Methods for treating non-cancerous disorders using hematopoietic cells
US10881692B2 (en) 2018-04-05 2021-01-05 Medeor Therapeutics, Inc. Compositions for establishing mixed chimerism and methods of manufacture thereof
US10842821B2 (en) 2018-04-05 2020-11-24 Medeor Therapeutics, Inc. Cellular compositions derived from prior organ donors and methods of manufacture and use thereof
US11435350B2 (en) 2018-09-18 2022-09-06 Medeor Therapeutics, Inc. Methods of analysis of blood from deceased donors
US11813376B2 (en) 2018-09-18 2023-11-14 Medeor Therapeutics, Inc. Cellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5772994A (en) * 1993-05-28 1998-06-30 The University Of Pittsburgh Hematopoietic facilitatory cells and their uses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5772994A (en) * 1993-05-28 1998-06-30 The University Of Pittsburgh Hematopoietic facilitatory cells and their uses

Also Published As

Publication number Publication date
WO2002040640A2 (en) 2002-05-23
AU2002220031A1 (en) 2002-05-27

Similar Documents

Publication Publication Date Title
WO2002040640A3 (en) Methods of using cd8+/tcr- facilitating cells (fc) for the engraftment of purified hematopoietic stem cells (hsc)
Van Lochern et al. In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities
WO2003006950A3 (en) Cells of the cardiomyocyte lineage produced from human pluripotent stem cells
WO2003068937A3 (en) Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
WO2002028905A3 (en) Human anti-cd40 antibodies
WO2003012060A3 (en) Cellular compositions which facilitate engraftment of hematopoietic stem cells while minimizing the risk of gvhd
ATE365045T1 (en) PRODUCTION OF SOFT AND BONE TISSUE USING PRECURSOR CELLS FROM MUSCLE, AS WELL AS ASSOCIATED COMPOSITIONS AND FORMS OF TREATMENT
EA200601231A1 (en) DEFINITIVE ENTODERMA
WO2003059276A3 (en) Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
WO2004070013A3 (en) Use of islet 1 as a marker for isolating or generating stem cells
MX2008007286A (en) In vivo cell surface engineering.
MXPA03006699A (en) Methods of inducing organ transplant tolerance and correcting hemoglobinopathies.
CA2390281A1 (en) Hematopoietic differentiation of human embryonic stem cells
SG152273A1 (en) Pdx1 expressing endoderm
RS52389B (en) Heterocyclic compound based on n6-substituted adenine methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing thes
MX2009014273A (en) Methods and compositions for optimized expansion and implantation of mesenchymal stem cells.
BR0210599A (en) Use of carbon monoxide, method for maintaining an animal cell in vitro, article of manufacture as well as sterile cell medium
HK1052950A1 (en) Purging of cells using viruses.
WO2005030040A8 (en) Hematopoietic stem cell identification and isolation
EP3031470A3 (en) Manipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists
BR9612821A (en) Methods for preventing graft rejection in transplantation and for producing a host cell for universal gene therapy
WO2011106703A3 (en) Cxcr4 receptor compounds
WO2004063341A3 (en) Hematopoietic stem cell niche cells
WO2003080798A3 (en) Muscle cells and their use in cardiac repair
ATE399854T1 (en) HEMATOPOETIC ßFACILITATORYß CELLS AND THEIR USE

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP